METHOXACET-C 1/8 8 MG
CODEINE PHOSPHATE : 8 MG ACETAMINOPHEN : 325 MG METHOCARBAMOL : 400 MG · DIN 02236872 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is METHOXACET-C 1/8?
METHOXACET-C 1/8 8 MG contains CODEINE PHOSPHATE : 8 MG ACETAMINOPHEN : 325 MG METHOCARBAMOL : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02236872, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 12-Nov-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02236872 |
|---|---|
| Brand name | METHOXACET-C 1/8 |
| Generic / active ingredient | CODEINE PHOSPHATE : 8 MG ACETAMINOPHEN : 325 MG METHOCARBAMOL : 400 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 8 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA59 CODEINE, COMBINATIONS EXCL. PSYCHOLEPTICS |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 12-Nov-2018 |
What can be used instead?
Other Canadian products sharing ATC code N02AA59 CODEINE, COMBINATIONS EXCL. PSYCHOLEPTICS. 1 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ROBAXACET-8 | 400 MG | TABLET | HALEON CANADA ULC | MARKETED | DIN 01934767 |
| AXACET-C1/8 | 8 MG | TABLET | TECHNILAB PHARMA INC. | CANCELLED (UNRETURNED ANNUAL) | DIN 02237996 |
| AXISAL-C1/8 | 8 MG | TABLET | TECHNILAB PHARMA INC. | CANCELLED (UNRETURNED ANNUAL) | DIN 02237997 |
| METHOXISAL-C 1/2 | 32.4 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 01966375 |
| METHOXISAL-C 1/4 | 16.2 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 01966367 |
| METHOXISAL-C 1/8 | 8 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 01941895 |
| MUSCLE & BACK PAIN RELIEF - 8 | 325 MG | TABLET | VITA HEALTH PRODUCTS INC | CANCELLED POST MARKET | DIN 02242180 |
| MUSCLE & BACK PAIN RELIEF-8 | 400 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02243047 |
| MUSCLE AND BACK PAIN RELIEF CAPLETS | 8 MG | TABLET | JAMP PHARMA CORPORATION | APPROVED | DIN 02258978 |
| MUSCLE AND BACK PAIN RELIEF-8 | 400 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02248977 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.